Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction : Results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program

摘要: Objectives We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in Candesartan Heart failure-Assessment Reduction Mortality and morbidity (CHARM) program, which enrolled patients chronic heart failure (CHF) a broad range ejection fractions (EFs). Background Atrial is an increased CV CHF reduced EF. The AF preserved left ventricular fraction (PEF) unknown. Methods A total 7,599 symptomatic were randomized to candesartan or placebo. Patients divided by baseline EF (≤40% >40%) low groups. Major death hospitalization for worsening failure, all-cause mortality. Median follow-up was 37.7 months. Results 670 (17%) group 478 (19%) PEF had at baseline. predicted high mortality regardless highest absolute outcomes. However, greater relative major than EF: hazard ratio 1.72 (95% confidence interval [CI] 1.45 2.06) versus 1.29 CI 1.14 1.46), respectively. same true similar treatment effects rhythm. Conclusions either PEF. improved similarly